A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Moxr0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2019
Price : $35 *
At a glance
- Drugs Vonlerolizumab (Primary) ; Atezolizumab
- Indications Urogenital cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 30 May 2019 Status changed from completed to discontinued.
- 10 May 2018 Status changed from active, no longer recruiting to completed.
- 22 Jan 2018 Planned End Date changed from 1 Jun 2019 to 29 Jun 2019.